Ximluci®
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
9/11/2022
STATUS:
Authorized
ACTIVE PRINCIPLE:
ranibizumab
INDICATION:
wet macular degeneration
Macular edema
Diabetic retinopathy
diabetic complications
DATE:
9/11/2022
STATUS:
Authorized